Sign in
TerminatedNo phase

Dual-target, High-dose TMS for PD Patients With FOG

Key facts

Who runs it
Anhui Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
64 people enrolled
Started
22 Dec 2022
Ended
31 Mar 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • transcranial magnetic stimulation
Record updated
19 November 2025
Why it stopped
The study was halted at the midpoint because the interim analysis demonstrated a large effect size of the DHT group compared with the SCT group (Cohen's d = 1.58).

Who can take part

Age
40 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • diagnosis of FOG with expertise in movement disorders
  • the score of item 3 of the FOG questionnaire ≥1
  • ongoing treatment with a stable dose of any medication for 2 months
  • 40 years of age or older

Who cannot take part

  • anti-PD medication adjustments during rTMS treatment
  • previously received rTMS treatment
  • prior history of seizure or history in first-degree relatives
  • a history of addiction, psychiatric disorders, or neurological diseases other than PD
  • history of substance abuse within the past 6 months
  • focal brain lesions on T1-/T2-weighted fluid-attenuated inversion recovery images
  • nonremovable metal objects in or around the head

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of the current study was to verify whether high-dose TMS treatment of the motor and cognitive cortices is more effective in alleviating FOG than conventional-dose TMS of the motor cortex only. Specifically, investigator hypothesized that the effect of dual-target TMS on FOG is better than traditional stimulation of the motor cortex only, and the effect of high-dose TMS is better than conventional doses.

The 3 groups in the trial

  • Dual-target high-dose TMS (DHT)Treatment being tested

    DHT refers to the left primary motor cortex of the lower leg (M1) and dorsolateral prefrontal cortex (DLPFC) receiving 9000 pulses/day of intermittent TBS (iTBS) for 5 consecutive days. Each iTBS sequence in the high-dose stimulation sequence released 900 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of 10 iTBS sessions was performed each day with an interval of 40 min and the daily stimulation dose was 9000 pulses. The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session.

    Treatment: transcranial magnetic stimulation

  • Dual-target conventional-dose TMS (DCT)Treatment being tested

    DCT refers to the left M1 and DLPFC receiving 1800 pulses/day of iTBS for 5 consecutive days. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session.

    Treatment: transcranial magnetic stimulation

  • Single-target conventional-dose TMS (SCT)Existing treatment, for comparison

    SCT refers to the left M1 receiving 1800 pulses/day of iTBS treatment for 5 consecutive days. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.

    Treatment: transcranial magnetic stimulation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dual-target, High-dose, Transcranial Magnetic Stimulation for Parkinson's Disease With Freezing of Gait
Record updated
19 November 2025